Home / Policies & Legislation / India to delink marketing authorisation and patent status
India to delink marketing authorisation and patent status Posted 07/01/2011
Marketing approvals for generic drugs may soon be delinked from their patent status in India. This comes as a result of long-standing demand from India’s pharmaceutical industry, which depends heavily on the sale of generic drugs.
The health ministry is planning to remove a question on the patent status of a drug from the form that medicine companies fill in when applying to the Drug Controller General of India (DCGI) for regulatory approval, a ministry official said. The proposal follows a meeting in Mumbai, India, in November 2010 between Indian drugmakers and Health Minister Ghulam Nabi Azad. If deleted, the DCGI will issue approvals only on the grounds of drug quality and efficacy. The issue will be taken up at the next Drug Testing Advisory Board meeting.
Source: Livemint
Comments (0)
Sign up today to receive weekly news on the latest developments in generic and biosimilar medicines!
Generics News Research General
- Clopidogrel goes off-patent: last of the old-st...Generics/General | Posted 18/05/2012
- Generic atorvastatin could save NHS GBP 350 mil...Generics/News | Posted 18/05/2012
- Can generic competition succeed at reducing cos...Generics/Research | Posted 11/05/2012
- Also noted on generics: 11 May 2012Generics/General | Posted 11/05/2012
Biosimilars News Research General
- Biosimilar filgrastim provides cost savings for...Biosimilars/Research | Posted 11/05/2012
- US Supreme Court looks set to challenge Afforda...Biosimilars/General | Posted 18/05/2012
- Biosimilars approved and marketed in BelgiumBiosimilars/General | Posted 18/05/2012
- Daiichi Sankyo and Coherus BioSciences make bio...Biosimilars/News | Posted 18/05/2012